Table 2 Treatment’s details
Treatment | N (%) | |
|---|---|---|
PD-1 inhibitors | Pembrolizumab | 14 (14.9) |
Camrelizumab | 12 (12.8) | |
Tislelizumab | 12 (12.8) | |
Sintilimab | 15 (16.0) | |
Toripalimab | 41 (43.6) | |
Cycles of PD-1 inhibitors | Median (range) | 10 (1–44) |
Chemotherapy | Yes | 90 (95.7) |
No | 4 (4.3) | |
Cycles of chemotherapy | Median (range) | 4 (1–8) |
Radiotherapy | SBRT | 187 (67.8) |
Hypofractionated | 89 (32.2) | |
Dose of radiotherapy | Median (range) | 52.3 Gy (24–60 Gy) |